Biosimilar Insights
-
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim
5/5/2024
From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software startups. But Slonim's not in software development anymore.
-
Be A Gain Changer, 2x Throughput, Only With Supor Prime
5/4/2024
Highly concentrated antibody drugs hold promise in revolutionizing patient treatment. However, new treatments bring forth new challenges in manufacturing. Engineered to deliver the high throughput capacity of high-value drug products, Cytiva Supor™ Prime filters minimize product loss and waste, guaranteeing optimal yield. Watch to learn more about these innovative filters.
-
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
4/28/2024
As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.
-
Bulk Filling Of Drug Substance | Accurate Aliquoting
4/24/2024
Bulk filling drug substances in traditional facilities is often a lengthy, manual process where operators are relied upon to adjust pump controls to achieve accurate filling. This method, spanning multiple shifts, increases process risk through errors that can compromise accuracy.
-
5 Areas To Focus Your QRM Strategy - Sterile Drug Products
4/24/2024
Explore five areas that can form part of a quality risk management strategy to ensure the compliant manufacturing of sterile drug products
-
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.
4/21/2024
Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO.
-
Strategies For Scaling Up mRNA Manufacturing To Address Vaccine Demand
4/17/2024
Learn how flexible approaches can help address the considerations and hurdles in mRNA manufacturing.
-
A Rentschler Collaboration Story
4/17/2024
Learn how a collaboration between Cytiva and Rentschler Biopharma facilitates the efficient and flexible production of viral vectors.
-
Tips For Viral Vector Production
4/16/2024
Learn about how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.
-
What Is A Viral Vector?
4/16/2024
Review a novel adenovirus production process that offers scalable, single-use equipment-compatible solutions, reducing production time and cross-contamination risks.